Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 3/2005

01-09-2005 | Original Article

Potential for drug interactions in hospitalized cancer patients

Authors: Rachel Pimenta Riechelmann, Frederico Moreira, Òren Smaletz, Everardo D. Saad

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2005

Login to get access

Abstract

Objectives

To quantify the frequency of potential drug interactions unrelated to chemotherapy in cancer patients admitted to our institution, and to define risk factors for such interactions.

Methods

Charts of 100 consecutive hospitalized cancer patients were reviewed. Patients receiving chemotherapy and/or hormone therapy were excluded, as were patients admitted for intensive care. Drug–drug interactions were screened with Drug Interaction Facts software, and manually by the authors. Potential interactions were graded by levels of severity (severe, moderate, minor) and significance (one to five, with one representing the highest level of evidence).

Results

The median age of the patients was 67 years, and the length of hospital stay and the number of drugs per patient were 6 days and eight drugs, respectively. In 63 patients 180 potential interactions were detected. Of the potential interactions, 18.3% were severe, 56.7% were moderate, and 25% were minor. Approximately 7%, 18% and 13% of potential interactions were graded as level 1, 2 and 3, respectively. In multivariate analysis, prescriptions with eight or more drugs (P=0.0004) and six or more days of hospital stay (P=0.014) were independent risk factors for potential interactions.

Conclusion

Potential drug interactions are common among hospitalized cancer patients. Length of hospital stay and number of prescribed drugs are risk factors.
Literature
1.
Barrons R (2004) Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm 61:380–385
2.
Beers MH, Storrie M, Lee G (1990) Potential adverse drug interactions in the emergency room. An issue in the quality of care. Ann Intern Med 112:61–64
3.
Bernard S, Bruera E (2000) Drug interactions in palliative care. J Clin Oncol 18:1780–1799
4.
Bjerrum L, Andersen M, Petersen G, Kragstrup J (2003) Exposure to potential drug interactions in primary health care. Scand J Prim Health Care 21:153–158CrossRefPubMed
5.
Buajordet I, Ebbesen J, Erikssen J, Brors O, Hilberg T (2001) Fatal adverse drug events: the paradox of drug treatment. J Intern Med 250:327–341
6.
Carbonin P, Pahor M, Bernabei R, Sgadari A (1991) Is age an independent risk factor of adverse drug reactions in hospitalized medical patients? J Am Geriatr Soc 39:1093–1099PubMed
7.
Ciummo PE, Katz NL (1995) Interactions and drug-metabolizing enzymes. Am Pharm NS35:41–51; quiz 51–53
8.
Corcoran ME (1997) Polypharmacy in the older patient with cancer. Cancer Control 4:419–428
9.
Craig C, Stiztel R (1997) Modern pharmacology with clinical application, 5th edn. Little Brown and Company, New York
10.
Daly MP, Lamy PP, Richardson JP (1994) Avoiding polypharmacy and iatrogenesis in the nursing home. Md Med J 43:139–144
11.
Davidson KW, Kahn A, Price RD (1987) Reduction of adverse drug reactions by computerized drug interaction screening. J Fam Pract 25:371–375
12.
Delafuente JC (2003) Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol 48:133–143
13.
14.
Egger SS, Drewe J, Schlienger RG (2003) Potential drug–drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol 58:773–778PubMed
15.
Fauno P, Petersen KD, Husted SE (1993) Increased blood loss after preoperative NSAID. Retrospective study of 186 hip arthroplasties. Acta Orthop Scand 64:522–524
16.
Gear RW, Miaskowski C, Heller PH, Paul SM, Gordon NC, Levine JD (1997) Benzodiazepine mediated antagonism of opioid analgesia. Pain 71:25–29
17.
Geppert U, Beindl W, Hawranek T, Hintner H (2003) Drug interactions in clinical practice. A pilot project for quality assurance in prescribing. Hautarzt 54:53–57
18.
Gerson LB, Triadafilopoulos G (2001) Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur J Gastroenterol Hepatol 13:611–616
19.
Glassman PA, Simon B, Belperio P, Lanto A (2002) Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Med Care 40:1161–1171CrossRefPubMed
20.
Goldberg RM, Mabee J, Mammone M, Chan L, Tarleton G, Broderick S, Robinson DC, Hurst AK, Whelan GP (1994) A comparison of drug interaction software programs: applicability to the emergency department. Ann Emerg Med 24:619–625
21.
Goldberg RM, Mabee J, Chan L, Wong S (1996) Drug–drug and drug–disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med 14:447–450
22.
Hancock D, Kennington JM, Beckner RR, Quick G (1992) Emergency department medication and drug interaction evaluation. Hosp Pharm 27:129–132
23.
Heininger-Rothbucher D, Bischinger S, Ulmer H, Pechlaner C, Speer G, Wiedermann CJ (2001) Incidence and risk of potential adverse drug interactions in the emergency room. Resuscitation 49:283–288
24.
Herr RD, Caravati EM, Tyler LS, Iorg E, Linscott MS (1992) Prospective evaluation of adverse drug interactions in the emergency department. Ann Emerg Med 21:1331–1336
25.
Hosmer DW, Lemeshow S (1989) Applied logistic regression. Wiley, New York
26.
Jankel CA, Martin BC (1992) Evaluation of six computerized drug interaction screening programs. Am J Hosp Pharm 49:1430–1435
27.
Karas S Jr (1981) The potential for drug interactions. Ann Emerg Med 10:627–630
28.
Lackner TE (1991) Interaction of dexamethasone with phenytoin. Pharmacotherapy 11:344–347
29.
McLeod HL (1998) Clinically relevant drug–drug interactions in oncology. Br J Clin Pharmacol 45:539–544
30.
Michocki RJ, Lamy PP, Hooper FJ, Richardson JP (1993) Drug prescribing for the elderly. Arch Fam Med 2:441–444
31.
Pick CG (1997) Antinociceptive interaction between alprazolam and opioids. Brain Res Bull 42:239–243
32.
Poirier TI, Giudici R (1995) Evaluation of drug interaction microcomputer software: an updated comparison. Hosp Pharm 30:888–890, 893–894
33.
Sternbach H (1991) The serotonin syndrome. Am J Psychiatry 148:705–713
34.
Tatro DS (ed) (1997) Drug interaction facts, 4th edn. Facts and Comparisons, St. Louis, MO
35.
Weale AE, Warwick DJ, Durant N, Prothero D (1995) Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement? Ann R Coll Surg Engl 77:35–37
Metadata
Title
Potential for drug interactions in hospitalized cancer patients
Authors
Rachel Pimenta Riechelmann
Frederico Moreira
Òren Smaletz
Everardo D. Saad
Publication date
01-09-2005
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 3/2005
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-004-0998-4

Other articles of this Issue 3/2005

Cancer Chemotherapy and Pharmacology 3/2005 Go to the issue

Original Article

P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing

Original Article

Preclinical pharmacology of epothilone D, a novel tubulin-stabilizing antitumor agent

Original Article

Effect of NQO1 induction on the antitumor activity of RH1 in human tumors in vitro and in vivo

Original Article

Structure-activity relationships of antineoplastic ring-substituted ether phospholipid derivatives

Original Article

Genistein-induced apoptosis via Akt signaling pathway in anaplastic large-cell lymphoma

Original Article

Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits